Alluvi, previously BI 4744, presents a notable breakthrough in obesity treatment. This dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates remarkable efficacy in https://bookmarkvids.com/story635228/alluvi-a-comprehensive-investigation-into-retatrutide-s-potential